Pharmacist Led Educational Intervention on QOL, Medication Adherence & Satisfaction on Pat
There was no previous study in Iraq to evaluate the efficacy of pharmacist-led educational intervention on patient glycemic control, quality of life and medication adherence among type 1 diabetic patients in Iraq. Improving diabetes patients' information's about their disease control, the role of insulin and the right
| Condition(s) | Diabetes Mellitus, Type 1 |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | There was no previous study in Iraq to evaluate the efficacy of pharmacist-led educational intervention on patient glycemic control, quality of life and medication adherence among type 1 diabetic patients in Iraq. Improving diabetes patients' information's about their disease control, the role of insulin and the right technique to administer it, how to deal with hyper- and hypoglycemia, about their diet and exercise. It is important to conduct a study to evaluate the pharmacist's role in education and improving patients' quality of life. |
| Who can participate | Inclusion Criteria: * \- Patients age ≥ 16 years old who can speak and read the Arabic language. * Had been diagnosed with T1DM for at least 6 months ago. * Had uncontrolled hyperglycemia (glycosylated hemoglobin HbA1C ≥7% and/or fasting blood glucose \>130 mg/dl) * Patients on the same regimen the last 3 months. * patients (or parents) acceptance to participate in the study. Exclusion Criteria: * 1-Patient who have hearing, speech or cognitive deficits that would impair understanding of the questions and receiving the education. 2- Patients with comorbid conditions that may interfere with the study such as asthma, thyroid disorders, adrenal gland disorders, celiac disease, or significant renal impairment. 3-Patients who are taking corticosteroids. 4- Patients who required changing their i |
| Ages | 16 Years |
| Sex | All |
| Lead sponsor | University of Baghdad |
| Locations | Baghdad, Iraq |
| Start date | 2024-02-01 |
| NCT ID | NCT06547970 |
| Official listing | https://clinicaltrials.gov/study/NCT06547970 |